HIGHLIGHTS
- who: Sahar F. Bannoura et al. from the Medical University of South Carolina, United States have published the research: KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?, in the Journal: (JOURNAL)
- what: Given the success of translating this discovery to the clinic, research efforts are focusing on drugging KRAS G12D, the most common hotspot mutation.
- future: Studies and clinical trials are needed to investigate this therapy on a larger scale and to identify other KRAS-G12D-reactive TCRs which could be utilized for similar therapies .
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.